LIDE’s Translational Medicine platform enables us to establish many acquired drug-resistant PDX models. Most of these models are generated from biopsy samples, not surgery samples like most other CROs. Most surgery samples are treatment naïve at clinic, making biopsy samples the preferred choice for establishing mouse models or cell lines. LIDE's PDX models, established from biopsy samples that have already developed acquired drug resistant in the patient, is a more relevant choice for drug screening. The partial list is below but please contact us for the most up to date models.
With CR(Conditional Reprogramming) technology, we areable to establish PDX matching cell lines for drug screening, Pro-RNAi, CRISPR, luciferase labelling etc. 100+ PDX matching cell lines are available. Please reference that list here.
| Cancer Type | Drug Resistance | Genetic Alteration |
| NSCLC | Erlotnib Osimertinib Crizotnib Brigatnib anti PD-1 ab |
EGFR: exon19del/T790M/L858R/C797S/exon20ins ALK: EML4-ALK/L11196M cMET: ampli./exon14ski/CD47-MET RET: KIF5B-RET ROS1: CD74-ROS1/G2032R KRAS: G12C P13K: E726K |
| Breast Cancer | CDK4/6i | TNB/ER+ |
| Multiple Myeloma | Bortezomib | CD47+/CD38+ |
| Cholangiocarcinoma | Paclitaxel | KRAS: G12C FGFR: BICC1-FGFR2 |
| Colorectal Cancer | Avastin | KRAS: G12C BFAR: V600E |
| Hematological Malignancy | Rituximab Imatinib |
/ |
| Gastric Cancer | Herceptin | HER2: ampli KRAS: G12/G13D |
| Brain Cancer | / | EGFR: VIII cMET: PTPPRZ1-MET |
| Melanoma | anti PD-1 ab | BRAF: V600E |
| Ovarian Cancer | Platinum PARpi |
/ |
Table: LIDE PDX models with drug resistance